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The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)-
Outcome Measures in Rheumatology (OMERACT) Psoriatic Arthritis (PsA) working group 
reported at the 2019 GRAPPA annual meeting on updates on the work towards a Core 
Outcome Measurement Set for PsA. Four domains have been prioritized including MSK 
disease activity (enthesitis and dactylitis), fatigue, physical function, and structural damage.  
Updates of the work progress of each domain were summarized.  
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Introduction 
The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 
(GRAPPA)-Outcome Measures in Rheumatology (OMERACT) Psoriatic Arthritis (PsA) 
Core Set working group has updated the Core Domain Set in 2016 (1, 2). The updated PsA 
Core Domain Set developed through a combined effort of health care professionals and 
patient research partners (PRPs), defined domains that are essential to be measured in all 
clinical trials (1, 2). Since then, the working group has begun the work to develop a PsA Core 
Outcome Measurement Sets (3).  At OMERACT in 2018, the 66/68 swollen and tender joint 
counts received endorsement for the measurement of “musculoskeletal (MSK) disease 
activity: peripheral joints” (4) and the PsAID12 received provisional endorsement for the 
domain of health related quality of life (5).  
Four domains have been prioritized for appraisal of the instruments, including MSK 
disease activity (enthesitis and dactylitis), fatigue, physical function, and structural damage. 
These 4 domains were chosen due to their importance in clinical trials and the urgent need to 
standardize instruments for the domains (6). This is a report of the working group’s 
presentation at the GRAPPA 2019 annual meeting in Paris, France where the work 
undertaken in standardizing the Core Outcome Measurement set for these 4 domains was 
presented. 
The overall work stream for each domain 
Dr Leung explained briefly that the appraisal of instruments for each domain follows 
the methodology lay out by the OMERACT Filter 2.1(6). The four pillars of the OMERACT 
Filter 2.1 consist of Truth 1 (Domain match), Feasibility, Truth 2 (Numerical sense) and 
Discrimination (7). The overall work stream plan for each of the 4 domains starts with 
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conveying a domain working group. Members of each domain working group comprise of 
health care professions with relevant expertise and at least 2 PRPs. Relevant instrument(s) for 
the domains will then be identified via systematic literature reviews. For domains that have 
numerous instruments available, the domain working groups may prioritize instruments 
through discussion and Delphi exercises to achieve consensus. Prioritized instruments for a 
domain would then be critically appraised using the OMERACT Filter 2.1. For some 
instruments, missing evidence may need to be identified. The working group has already 
developed and used specific methods for evaluating domain match by patient research 
partners. The appraisal processes with the OMERACT Filter 2.1 will be discussed with the 
OMERACT technical advisory group. The evidence supporting each instrument for a 
particular domain will be provided in the OMERACT summary of measurement properties 
table. The domain working groups will consider the evidence supporting each instrument and 
develop consensus via Delphi exercises. All documents derived for each instrument will be 
submitted to OMERACT for further endorsement. A new virtual voting method from 
OMERACT will be available that enables endorsement of instruments from the OMERACT 
community, rather than the standard voting workshop during the 2-yearly OMERACT 
congress.  
Updates on work stream for each prioritized domain 
MSK: Disease Activity: Enthesitis and Dactylitis 
 The MSK disease activity working group was led by Alexis Ogdie and included 3 
PRPs. The working group completed a systematic literature review of the instruments 
measuring dactylitis, enthesitis, and peripheral joint counts in March 2017.  The summary 
from the peripheral joint studies has now been published (4).  Since OMERACT 2018, the 
working group has been assembling similar summaries of the measurement property tables 
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for enthesitis and dactylitis.  Fewer studies have investigated the psychometric properties of 
these disease features.  Next steps will include a similar Delphi exercise to that performed for 
the joint counts and will also include patient engagement so as to understand the content 
validity of the measures of enthesitis and dactylitis from the patient perspective.   
Enthesitis can also be assessed using ultrasound. An independent working group, led 
by Lihi Eder, has been focussing on the measurement properties of sonographic assessed 
enthesitis and the group has performed a systematic literature review (SLR) on sonographic 
enthesitis scoring instruments for the assessment of enthesitis (8). A few sonographic 
enthesitis scoring instruments which were developed for spondyloarthritis have been 
identified but most have not been validated in PsA. None of these instruments has the 
potential to pass the OMERACT filter 2.1. Therefore, additional research is required before 
existing instruments for assessing enthesitis on ultrasound can be endorsed. 
Physical Function 
The physical function working group consisted of 13 members including 2 PRPs. The 
working group has international representation that spans across America, Asia and Europe. 
Based on data from a published SLR on patient-reported outcome measures (PROMs) in PsA 
(9), the working group has identified a list of PROMs that measure physical function for PsA. 
Additional newer instruments were recommended by working group members. Through 
discussions and two rounds of Delphi exercises, the working group has prioritized 6 patient 
PROMs. Each of these PROMs will be further appraised individually using the OMERACT 
Filter 2.1. These 6 PROMs are the Health Assessment Questionnaire (HAQ)– Disability 
index (DI), HAQ -Spine (S), modified (m) HAQ, multidimensional (MD) HAQ, the physical 
functioning domain of the Medical Outcome Survey Short Form – 36 (SF-36-PF) and 
Patient-Reported Outcomes Measurement Information System – physical function (PROMIS-
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PF). The working group is working on a SLR evaluating the RCT discrimination of various 
PROMs for physical function.  
The appraisal document for HAQ-DI has been submitted to OMERACT for virtual 
voting. The SF-36-PF will be appraised next. The other PROMs will require synthesis of new 
data before formal appraisal using the OMERACT Filter 2.1. 
Fatigue 
Fatigue is a PsA core domain that is variably measured in PsA clinical trials 
(10).Evidence supporting fatigue instruments in PsA has been summarized in the above 
mentioned systematic literature review in PROMs (9).  The instruments that had 
psychometric evidence in PsA were FACIT-Fatigue, Fatigue visual analog scale (VAS), 
Fatigue numerical rating scale (NRS), and the Vitality component of the SF-36 form.  New 
evidence has emerged for fatigue instruments in PsA since the publication of the SLR 
including RCT thresholds for improvement for FACIT-Fatigue  and the Fatigue NRS (11) as 
well as the FACIT-Fatigue content validity.  A challenge for the appraisal of VAS and NRS 
single items is the standardization of the wording and time interval (past 7 days, today). A 
Fatigue working group led by Dr Orbai has been convened The Fatigue working group will 
consider the fatigue instruments as identified above (9), instruments used in prior PsA studies 
such as Fatigue Severity Score, Fatigue Assessment Scale, PROMOS-Fatigue and single 
fatigue-items included in the BASDAI and PsAID questionnaires (10).  Similar to the 
prioritization process undertaken for the Physical Function domain, the working group will 
use discussion and Delphi exercises to prioritize instruments which will undergo further 
evaluation using the OMERACT Filter 2.1.   
Commented [OF17]: Is this the same reference 11? 
Commented [OF18]: Add numbers in working group incl 
PRPs 
Structural Damage  
Dr Tillett and Dr Antony reviewed progress from the structural damage group. Unlike 
domains in the inner circle which are mandatory in all RCTs, the assessment of structural 
damage is placed in the middle circle of the core domain set where inhibition of structural 
damage is seen as important to be demonstrated at least once during drug development but 
not required to be measured in all clinical trials (2). As a result, structural damage has been 
prioritized by the OMERACT working group for selection of measurement instruments 
despite its position in the middle circle of the core domain set. The structural damage 
working group is conducting a SLR of imaging instruments for the assessment of structural 
damage in PsA. The group discussed how the literature review data should be reported and it 
was agreed that data relating to plain radiographic instruments would be reported first 
followed by the other imaging modalities including Magnetic Resonance Imaging, 
Ultrasound and Computed Tomography.  
Composites 
Composite indices are commonly used in rheumatology for the combined assessment 
of disease as well as for defining a treatment target or disease state. They typically span 
across several domains to encompass a broader concept of disease activity and disease impact. 
Several composite indices have been developed specifically for PsA and used in RCTs (12), 
but no consensus has been achieved of on which instrument to take forward (13). and the 
process for validation of composite indices is yet to be clarified within OMERACT. A 
workshop on composite indices in PsA was undertaken at the GRAPPA annual meeting and it 
is reported separately. 
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Conclusion 
This report summarized the work progress of GRAPPA-OMERACT PsA Core Set 
working group in a combined effort to a standardized Core Outcome Measurement Set. We 
have described an additional four prioritized domains including MSK disease activity 
(enthesitis and dactylitis), fatigue, physical function, and structural damage and we have 
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